RAPP earnings analysis
What we found in RAPP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Rapport reported no Q2 collaboration revenue and a net loss of $56.6 million ($1.19 per diluted share), versus a $26.7 million loss a year earlier, as R&D spending increased to $51.4 million from $22.7 million to support RAP-219’s Phase 3 program. The company generated $20.0 million of Tenacia collaboration revenue in the first half, but development intensity drove six-month operating cash use up to $54.5 million from $45.3 million. Liquidity remains strong at $436.1 million with runway projected into the second half of 2029, while the key near-term value drivers are bipolar-mania topline data expected in October 2026 and FOS open-label data expected in Q4 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- RAP-219 Phase 3 program initiated
- RAP-219 entered Phase 3 trials in drug-resistant focal-onset seizures during Q2 2026. Management expects topline bipolar-mania Phase 2 data in October 2026 and data from the FOS open-label safety study in Q4 2026.
- Cash runway projected into 2H 2029
- Cash, cash equivalents and short-term investments were $436.1 million at June 30, 2026. Management believes this balance funds operations and capital expenditures into the second half of 2029.
- Tenacia deal adds non-dilutive funding
- The Tenacia China license generated $20.0 million of collaboration revenue in the first six months of 2026; Rapport is also eligible for up to $308.0 million in sales milestones plus mid-single-digit to mid-teens royalties.
- Longer RAP-219 half-life supports dosing profile
- RAP-219’s estimated half-life increased to 22 days from the prior 14-day estimate, with management citing sustained therapeutic plasma concentrations during the 8-week follow-up period.
- Interest income rose to $4.2 million
- Interest income increased $1.4 million year over year to $4.2 million in Q2, partially offsetting the higher development spend.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Loss and expense base increased sharply
- Q2 net loss widened to $56.6 million, or $1.19 per diluted share, from a $26.7 million loss a year earlier. Total operating expense more than doubled to $60.8 million from $29.5 million.
- Phase 3 spending materially accelerates
- R&D expense rose $28.7 million year over year to $51.4 million, led by a $24.4 million increase in RAP-219 program costs; $22.3 million of that increase was clinical-trial cost, principally Phase 3 start-up and other RAP-219 studies.
- Operating cash burn increased
- Six-month operating cash use rose to $54.5 million from $45.3 million a year earlier. The company had $436.1 million of cash and short-term investments but states it will need substantial additional capital in the future.
- Pipeline remains exposed to trial and FDA risk
- The business remains fully dependent on clinical and regulatory execution: RAP-219 is only now in Phase 3 for FOS, while the company previously received an FDA clinical hold on the DPNP IND in Q4 2024, although that hold was removed in December 2025.
- $150.0 million ATM creates dilution capacity
- Potential future dilution remains material: the company had not sold shares through its ATM as of June 30, 2026, but has a sales agreement prospectus permitting up to $150.0 million of common-stock issuance.
- Janssen milestones could pressure future cash
- RAP-219 carries substantial contingent obligations under the Janssen license, including up to $76.0 million in development milestones and $40.0 million in sales milestones for the lead TARPγ8 candidate.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.19
What they said about what is next.
No numeric revenue or EPS outlook was provided in the 10-Q. Management expects $436.1 million of cash, cash equivalents and short-term investments at June 30, 2026 to fund operating expenses and capital expenditures into the second half of 2029; bipolar-mania Phase 2 topline data are expected in October 2026, open-label FOS data in Q4 2026, and a PGTCS Phase 3 initiation in the first half of 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Rapport Therapeutics reported a collaboration revenue of $20 million for Q1 2026, resulting in an improved net loss of $19.9 million from a loss of $24.1 million in the prior year. The company continues to invest…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RAPP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever